• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Tau Medical Ltd. - Warrant (NQ:DRTSW)

    3.500 -0.390 (-10.03%)
    Streaming Delayed Price Updated: 2:40 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 25,426
    Open 3.770
    Bid (Size) 3.500 (1,500)
    Ask (Size) 3.580 (300)
    Prev. Close 3.890
    Today's Range 3.350 - 3.850
    52wk Range 0.2250 - 4.280
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire

    Performance

    YTD
    +845.9%
    +845.9%
    1 Month
    +7.5%
    +7.5%
    3 Month
    +98.9%
    +98.9%
    6 Month
    +215.3%
    +215.3%
    1 Year
    +1196.3%
    +1196.3%

    More News

    Read More
    News headline image
    Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
    From Alpha Tau Medical Ltd.; Tolmar Inc.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Alpha Tau Medical Ltd. - Warrant publicly traded?
    Yes, Alpha Tau Medical Ltd. - Warrant is publicly traded.
    What exchange does Alpha Tau Medical Ltd. - Warrant trade on?
    Alpha Tau Medical Ltd. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for Alpha Tau Medical Ltd. - Warrant?
    The ticker symbol for Alpha Tau Medical Ltd. - Warrant is DRTSW on the Nasdaq Stock Market
    What is the current price of Alpha Tau Medical Ltd. - Warrant?
    The current price of Alpha Tau Medical Ltd. - Warrant is 3.500
    When was Alpha Tau Medical Ltd. - Warrant last traded?
    The last trade of Alpha Tau Medical Ltd. - Warrant was at 08/12/26 02:40 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.